Welcome to our dedicated page for Centessa Pharmaceuticals Plc SEC filings (Ticker: CNTA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Centessa Pharmaceuticals plc (CNTA) SEC filings page provides access to the company’s U.S. regulatory disclosures, including current reports on Form 8‑K and related exhibits. As a Nasdaq-listed issuer with ordinary shares and American Depositary Shares registered under Section 12(b) of the Exchange Act, Centessa files documents that describe material events, financing transactions, governance matters and other information relevant to CNTA shareholders.
Recent Forms 8‑K detail items such as underwriting agreements for public offerings of American Depositary Shares, an amended and restated at-the-market sales agreement, financial results for quarterly periods, and the clearance of an Investigational New Drug (IND) application for ORX142. Filings also cover outcomes of the company’s annual general meeting, including director elections, auditor re-appointment and share allotment authorities, as well as executive employment arrangements reported under Item 5.02.
Through this page, users can review how Centessa reports progress and risks around its clinical-stage orexin receptor 2 (OX2R) agonist pipeline, capital-raising activities, and other significant corporate actions. Forms 8‑K that reference press releases often include clinical and financial updates, while accompanying exhibits such as sales agreements, underwriting agreements and legal opinions provide additional detail on transaction structures and securities law matters.
Stock Titan enhances these filings with AI-powered summaries that highlight key terms, sections and implications, helping readers quickly understand complex documents such as offering-related 8‑Ks and governance disclosures. Investors can use this resource to monitor CNTA’s regulatory reporting history, track new filings as they appear on EDGAR in near real time, and identify information relevant to their own analysis of the company.
Centessa Pharmaceuticals awarded its Chief Financial Officer, John J. Crowley, new equity incentives. He received 45,000 Ordinary Shares as restricted share units that vest in four equal annual installments starting on February 2, 2027. The company also granted a share option for 181,000 Ordinary Shares with an exercise price of $25.19, expiring on February 2, 2036. This option vests in 48 equal monthly installments, beginning on March 2, 2026. These grants increase his direct beneficial ownership to 45,000 shares and 181,000 options, aligning his compensation more closely with the company’s future share performance.
Centessa Pharmaceuticals plc’s Chief Accounting Officer, Raphael Deferiere, reported new equity awards. On February 2, 2026, he received 11,000 Ordinary Shares as Restricted Share Units at $0 cost, bringing his directly held Ordinary Shares to 11,000.
He was also granted a share option for 42,000 Ordinary Shares at an exercise price of $25.19 per share, expiring on February 2, 2036. These options vest in equal monthly installments over 48 months starting March 2, 2026, while the RSUs vest in four equal annual installments beginning February 2, 2027.
Centessa Pharmaceuticals' Chief Legal Officer J Iqbal Hussain reported multiple equity transactions in Centessa Pharmaceuticals plc Ordinary Shares. On January 30, 2026, he sold 1,010 Ordinary Shares at a weighted average price of $25.0109. On February 1, 2026, 7,780 shares were withheld to cover tax obligations tied to vesting restricted share units at $24.57 per share.
On February 2, 2026, he sold an additional 38,951 Ordinary Shares at a weighted average price of $25.151, and received 40,000 restricted share units that vest in four equal annual installments starting February 2, 2027, plus 20,000 restricted share units that vest on February 2, 2027. He also received a share option for 160,000 Ordinary Shares at an exercise price of $25.19, vesting monthly over 48 months starting March 2, 2026. After these transactions, he directly beneficially owned 117,645 Ordinary Shares and indirectly 5,500 Ordinary Shares through his spouse, in addition to the 160,000-share option.
Centessa Pharmaceuticals’ Chief Business Officer Gregory M. Weinhoff reported new equity compensation and related share withholding. On February 1, 2026, 14,158 ordinary shares were withheld at $24.57 each to cover taxes on vesting restricted share units, leaving 108,121 shares owned directly.
On February 2, 2026, he received 31,000 restricted share units at $0, bringing his direct holdings to 139,121 ordinary shares. These RSUs vest in four equal annual installments starting February 2, 2027. He also was granted a share option for 123,000 ordinary shares at an exercise price of $25.19, vesting in 48 equal monthly installments beginning March 2, 2026 and expiring February 2, 2036.
Centessa Pharmaceuticals’ Chief Executive Officer Mario Alberto Accardi reported routine equity compensation and related tax withholding transactions in the company’s ordinary shares.
On February 1, 2026, 2,915 ordinary shares were withheld by Centessa to cover tax obligations tied to restricted share unit vesting, leaving him with 175,886 shares held directly. On February 2, 2026, he received 68,000 restricted share units for no cash cost, increasing his directly held ordinary shares to 243,886. The RSUs vest in four equal annual installments starting February 2, 2027.
Also on February 2, 2026, he was granted a share option for 273,000 ordinary shares at an exercise price of $25.19 per share. The option vests in equal monthly installments over 48 months, with the first installment vesting on March 2, 2026. Following this grant, he beneficially owns 273,000 options directly. Each ordinary share may be represented by one American Depositary Share.
Centessa Pharmaceuticals Chief People Officer Karen M. Anderson reported routine equity compensation and related tax withholding. On February 1, 2026, the company withheld 10,606 Ordinary Shares at a price of $24.57 per share to satisfy tax obligations on vesting restricted share units, leaving her with 43,716 directly owned Ordinary Shares.
On February 2, 2026, she received 29,000 Restricted Share Units under the company’s 2021 Stock Option and Incentive Plan, bringing her direct Ordinary Share holdings to 72,716. These RSUs vest in four equal annual installments starting February 2, 2027. She was also granted a share option for 117,000 Ordinary Shares at an exercise price of $25.19 per share, vesting in equal monthly installments over 48 months starting March 2, 2026, with an expiration date of February 2, 2036.
Centessa Pharmaceuticals reported insider equity activity for Chief Technology & Quality Officer Tia L. Bush. On February 1, 2026, the company withheld 8,549 Ordinary Shares at $24.57 per share to satisfy tax obligations tied to vesting restricted share units.
On February 2, 2026, Bush received 35,000 Restricted Share Units at no cost, each representing one Ordinary Share, which will vest in four equal annual installments starting February 2, 2027. On the same date, she was also granted a share option for 140,000 Ordinary Shares at an exercise price of $25.19 per share, vesting in 48 equal monthly installments beginning March 2, 2026 and expiring on February 2, 2036. Following these transactions, she directly owned 147,954 Ordinary Shares and 140,000 share options.
Centessa Pharmaceuticals’ affiliate plans to sell common stock under Rule 144. A person named Iqbal Hussain filed to potentially sell 39,961 shares of Centessa common stock through UBS Financial Services Inc., with an aggregate market value of 1,019,005, on or after 01/30/2026 on NASDAQ.
The shares to be sold were acquired via restricted stock units (RSUs) from the issuer on multiple dates in 2024 and 2025. Over the prior three months, Hussain also sold 6,000 stock option shares for gross proceeds of 165,835.
A holder has filed a Rule 144 notice to sell 2,300,000 shares of Class A common stock through UBS Financial Services, with an aggregate market value of $52,601,000, targeting an approximate sale date of 01/21/2026 on NASDAQ. The form also lists 1,344,478 shares as the number of shares or other units outstanding.
The shares to be sold were acquired on 01/21/2026 via a stock option exercise from the issuer, paid in cash. Over the prior three months, the same seller, Saurabh Saha, reported multiple open-market sales of common stock, including 124,335 shares on 01/02/2026 for $2,976,499 and 1,100,000 shares on 01/15/2026 for $24,666,295, along with several other sizable transactions in early January.
Centessa Pharmaceuticals plc filed an amendment detailing the employment agreement for its incoming Chief Executive Officer, Dr. Mario Alberto Accardi, effective January 1, 2026. Under the agreement, Dr. Accardi will receive a base salary of $600,000 and be eligible for a target annual bonus equal to 50% of his base salary. If the company terminates his employment without cause, or he resigns for good reason outside the one-year period following a sale event under the 2021 Stock Option and Incentive Plan, he will receive 12 months of salary continuation. If his employment is terminated without cause or he resigns for good reason within one year after a sale event, he will receive a lump sum equal to 18 months of base salary plus 150% of his target bonus for the year of termination. The agreement also includes provisions to adjust any payments that could be treated as parachute payments under Sections 280G and 4999 of the U.S. tax code.